Full FDA Non-Device CDS disclaimer

ARKA Clinical Decision Support is designed to meet all four criteria for Non-Device CDS under FD&C Act §520(o)(1)(E) and FDA's January 2026 final guidance on Clinical Decision Support Software. Recommendations support, not replace, the clinician's judgment. Every recommendation is anchored in a published guideline or peer-reviewed source, with the basis available for independent review. CLIN emphasizes imaging appropriateness at order entry.

This recommendation is intended to support, not replace, clinical judgment. It is generated by ARKA, software designed to meet the four criteria for Non-Device Clinical Decision Support under FD&C Act §520(o)(1)(E) and FDA's final guidance on Clinical Decision Support Software (January 2026). The clinician is responsible for the final decision.

Regulatory rationale Feature catalog Trust center

Evidence library

AIIE Evidence

Red-flag symptoms — when imaging thresholds drop

Cross-Cutting Principles

Last reviewed 2026-06-01

Knowledge Matrix v1.0.0

Clinical bottom line

Red flags lower the imaging threshold and bypass watch-and-wait periods; their absence is the evidence basis for deferring imaging in uncomplicated presentations.

Summary

Red flags are history and exam findings — cancer history, fever with infection risk, new neurologic deficit, anticoagulation, constitutional symptoms — that raise the pre-test probability of serious pathology enough to bypass conservative-care waiting periods. They are sensitivity tools: most red-flag-positive patients still have benign disease, but their absence is what safely defers imaging.

Key points

Individual red flags vary widely in predictive value — cancer history is among the strongest.
Red flags work as a panel with clinical judgment, not as single mandatory triggers.
Document red-flag status explicitly: it is the audit trail for both imaging and deferral decisions.